CN103285015B - 三尖杉碱口服剂型 - Google Patents
三尖杉碱口服剂型 Download PDFInfo
- Publication number
- CN103285015B CN103285015B CN201210541508.3A CN201210541508A CN103285015B CN 103285015 B CN103285015 B CN 103285015B CN 201210541508 A CN201210541508 A CN 201210541508A CN 103285015 B CN103285015 B CN 103285015B
- Authority
- CN
- China
- Prior art keywords
- cephalotaxin
- dosage form
- peroral dosage
- administration
- homoharringtonine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Abstract
Description
组别 | 时间点(分钟) | 浓度(ng/mL) |
对照 | - | BQL |
1 | 15 | 3.54 |
1 | 30 | 3.59 |
1 | 60 | 3.85 |
1 | 120 | 4.29 |
1 | 240 | 1.81 |
1 | 480 | 1.65 |
2 | 15 | 20.4 |
2 | 30 | 11.2 |
2 | 60 | 6.20 |
2 | 120 | 3.59 |
2 | 240 | 2.44 |
2 | 480 | BQL |
3 | 15 | 6.58 |
3 | 30 | 8.87 |
3 | 60 | 29.9 |
3 | 120 | 9.18 |
3 | 240 | 5.52 |
3 | 480 | 4.19 |
4 | 15 | 54.4 |
4 | 30 | 15.4 |
4 | 60 | 35.3 |
4 | 120 | 6.38 |
4 | 240 | 7.72 |
4 | 480 | 3.10 |
粘性的 | 非粘性的 |
蛋白质类 | 蛋白质类 |
PDV1:10%明胶 | PDV2:牛血清白蛋白 |
脂质类 | 盐水类 |
LDV1:部分氢化的植物油 | SDV1:盐水 |
LDV2:硬脂醇 | |
碳水化合物类 | |
CDV1:蜂蜜 | |
CDV2:羟丙基纤维素 | |
组合 | |
LDV1:PDV1(1:1) |
Claims (11)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92346607P | 2007-04-13 | 2007-04-13 | |
US60/923,446 | 2007-04-13 | ||
CN200880017456A CN101677951A (zh) | 2007-04-13 | 2008-04-14 | 三尖杉碱口服剂型 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880017456A Division CN101677951A (zh) | 2007-04-13 | 2008-04-14 | 三尖杉碱口服剂型 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103285015A CN103285015A (zh) | 2013-09-11 |
CN103285015B true CN103285015B (zh) | 2016-04-27 |
Family
ID=40432102
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210541508.3A Expired - Fee Related CN103285015B (zh) | 2007-04-13 | 2008-04-14 | 三尖杉碱口服剂型 |
CN200880017456A Pending CN101677951A (zh) | 2007-04-13 | 2008-04-14 | 三尖杉碱口服剂型 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880017456A Pending CN101677951A (zh) | 2007-04-13 | 2008-04-14 | 三尖杉碱口服剂型 |
Country Status (8)
Country | Link |
---|---|
US (4) | US20090068236A1 (zh) |
EP (1) | EP2146690B1 (zh) |
JP (1) | JP5550546B2 (zh) |
KR (1) | KR101506607B1 (zh) |
CN (2) | CN103285015B (zh) |
AU (1) | AU2008240044B2 (zh) |
CA (1) | CA2684219C (zh) |
WO (1) | WO2008128191A2 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG174026A1 (en) | 2006-08-03 | 2011-09-29 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid disease |
CA2749646A1 (en) * | 2009-01-26 | 2010-07-29 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of asthma |
MX356111B (es) * | 2012-04-18 | 2018-05-15 | SpecGx LLC | Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata. |
CA2953396C (en) | 2014-07-03 | 2022-11-08 | Mallinckrodt Llc | Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides |
EP3856160A4 (en) | 2018-09-25 | 2022-07-06 | SpecGx LLC | ANTI-ABUSE IMMEDIATE RELEASE CAPSULES DOSAGE FORMS |
KR102174166B1 (ko) * | 2018-12-13 | 2020-11-04 | 영남대학교 산학협력단 | 호모해링토닌을 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물 |
CN110141664B (zh) * | 2019-05-28 | 2021-06-08 | 宁波市鄞州人民医院 | 一种治疗急性髓系白血病的药物组合物 |
KR102209386B1 (ko) * | 2020-01-09 | 2021-02-01 | 영남대학교 산학협력단 | 호모해링토닌을 유효성분으로 함유하는 대사질환 예방 또는 치료용 약학조성물 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3793454A (en) * | 1971-11-12 | 1974-02-19 | Us Agriculture | Harringtonine and isopharringtonine for treating l1210 or p388 leukemic tumors in mice |
US4152214A (en) * | 1977-10-07 | 1979-05-01 | The United States Of America As Represented By The Secretary Of Agriculture | Production of homodeoxyharringtonine and other cephalotaxine esters by tissue culture |
USH271H (en) * | 1984-08-06 | 1987-05-05 | The United States Of America As Represented By The Secretary Of The Army | Treatment of malaria with esters of cephalotaxine |
US4675318A (en) * | 1985-05-28 | 1987-06-23 | Yaguang Liu | Safe antileukemia drug, SAL |
US4675618A (en) * | 1986-06-09 | 1987-06-23 | Rockwell International Corporation | Linearizer circuit for frequency modulation oscillator |
DE3623331A1 (de) * | 1986-07-11 | 1988-01-21 | Hoechst Ag | Konfektionspackungen, enthaltend arzneimittelkombinationen fuer zeitlich abgestufte anwendung |
US5380747A (en) * | 1992-10-30 | 1995-01-10 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
EA200000087A1 (ru) * | 1997-07-01 | 2000-08-28 | Атеродженикс, Инк. | Повышение эффективности терапии гиперпролиферативных состояний с помощью антиоксиданта |
US6277395B1 (en) * | 1998-07-31 | 2001-08-21 | Ryukakusan Co. Ltd. | Swallowing-assistive drink |
US6025353A (en) * | 1997-11-19 | 2000-02-15 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents |
CA2315736A1 (en) * | 1998-01-05 | 1999-07-15 | Eisai Co., Ltd. | Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus |
FR2776292B1 (fr) * | 1998-03-20 | 2004-09-10 | Oncopharm | Cephalotaxanes porteurs de chaine laterale et leur procede de synthese |
AU757052B2 (en) * | 1998-09-09 | 2003-01-30 | Dart Neuroscience (Cayman) Ltd | Substituted gamma-phenyl-delta-lactones and analogs thereof and uses related thereto |
US6482828B1 (en) * | 1999-11-15 | 2002-11-19 | Parker Hughes Institute | 4-(4′-hydroxyphenyl) amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer |
ATE330611T1 (de) * | 2000-03-15 | 2006-07-15 | Chemgenex Pharmaceuticals Inc | Cephalotaxinalkaloid enthaltende kombinationspräparate und deren verwendung |
GB0006432D0 (en) * | 2000-03-17 | 2000-05-03 | Stanelco Fibre Optics Ltd | Capsules |
DE10045521A1 (de) * | 2000-03-31 | 2001-10-04 | Roche Diagnostics Gmbh | Nukleinsäureamplifikationen |
CA2404278C (en) * | 2000-04-12 | 2010-03-23 | Chemgenex Therapeutics, Inc. | Naphthalimide compositions and uses thereof |
BR0207930A (pt) * | 2001-03-05 | 2004-03-02 | Ortho Mcneil Pharm Inc | Composições farmacêuticas lìquidas com sabor mascarado |
TWI247612B (en) * | 2001-07-05 | 2006-01-21 | Shiseido Co Ltd | Powdered composition |
ATE548041T1 (de) * | 2001-09-05 | 2012-03-15 | Chemgenex Pharmaceuticals Ltd | Homoharringtonine allein oder in kombination mit anderen substanzen zur anwendung zur behandlung von chronischer myelogenischer leukemia resistent oder intolerant gegenüber proteinkinasehemmern ausgenommen sti 571 |
US20030124132A1 (en) * | 2001-09-27 | 2003-07-03 | Board Of Regents, The University Of Texas System | Combined compositions for tumor vasculature coaguligand treatment |
BR8201940U (pt) * | 2002-06-21 | 2004-05-11 | Wahler Metalurgica Ltda | Disposição construtiva aplicada em válvula termostática integrada à carcaça |
EP1534295A4 (en) * | 2002-07-17 | 2009-08-05 | Chemgenex Pharmaceuticals Inc | FORMULATIONS AND METHODS OF ADMINISTRATION OF CEPHALOTAXINS, INCLUDING HOMOHARRINGTONIN |
US7642252B2 (en) * | 2002-07-22 | 2010-01-05 | Chemgenex Pharmaceuticals, Inc. | Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof |
US20050101605A1 (en) * | 2003-11-07 | 2005-05-12 | Ahmed Salah U. | Oral liquid formulations of methotrexate |
EP1827434B1 (en) * | 2004-11-30 | 2014-01-15 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
RU2007137121A (ru) * | 2005-03-09 | 2009-04-20 | Оно Фармасьютикал Ко., Лтд. (Jp) | Частица и препарат, содержащий указанную частицу |
-
2008
- 2008-04-14 CA CA2684219A patent/CA2684219C/en not_active Expired - Fee Related
- 2008-04-14 US US12/102,643 patent/US20090068236A1/en not_active Abandoned
- 2008-04-14 CN CN201210541508.3A patent/CN103285015B/zh not_active Expired - Fee Related
- 2008-04-14 WO PCT/US2008/060251 patent/WO2008128191A2/en active Application Filing
- 2008-04-14 AU AU2008240044A patent/AU2008240044B2/en not_active Ceased
- 2008-04-14 JP JP2010503275A patent/JP5550546B2/ja not_active Expired - Fee Related
- 2008-04-14 CN CN200880017456A patent/CN101677951A/zh active Pending
- 2008-04-14 EP EP08799796.1A patent/EP2146690B1/en not_active Not-in-force
- 2008-04-14 KR KR1020097023728A patent/KR101506607B1/ko not_active IP Right Cessation
-
2011
- 2011-08-11 US US13/208,122 patent/US20110293676A1/en not_active Abandoned
-
2015
- 2015-12-23 US US14/757,838 patent/US20160193223A1/en not_active Abandoned
-
2018
- 2018-04-11 US US15/950,947 patent/US20180228813A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN103285015A (zh) | 2013-09-11 |
US20180228813A1 (en) | 2018-08-16 |
US20090068236A1 (en) | 2009-03-12 |
EP2146690A2 (en) | 2010-01-27 |
KR20090130129A (ko) | 2009-12-17 |
EP2146690B1 (en) | 2018-03-21 |
US20110293676A1 (en) | 2011-12-01 |
WO2008128191A2 (en) | 2008-10-23 |
CN101677951A (zh) | 2010-03-24 |
JP2010523723A (ja) | 2010-07-15 |
JP5550546B2 (ja) | 2014-07-16 |
WO2008128191A3 (en) | 2009-01-15 |
US20160193223A1 (en) | 2016-07-07 |
KR101506607B1 (ko) | 2015-03-30 |
AU2008240044A1 (en) | 2008-10-23 |
AU2008240044B2 (en) | 2013-09-12 |
CA2684219C (en) | 2017-05-23 |
CA2684219A1 (en) | 2008-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103285015B (zh) | 三尖杉碱口服剂型 | |
CN101184482B (zh) | 抑制胃酸分泌的组合物和其制备方法 | |
JP6480420B2 (ja) | コルヒチンの徐放性製剤およびその使用方法 | |
CN101083977B (zh) | 掩味药物组合物 | |
KR102094631B1 (ko) | 비만 및 관련 대사 장애의 치료를 위한 오를리스타트 및 아카르보스의 변형 방출형 조성물 | |
KR20040099265A (ko) | 신규의 치환 벤즈이미다졸 제형 및 그 사용방법 | |
US20070036860A1 (en) | Treatment of allergic conditions | |
BRPI0709745A2 (pt) | forma de dosagem oral, e, mÉtodo para prevenir ou reduzir a severidade, duraÇço, e/ou sintomas de um distérbio gastrintestinal | |
JP2010532358A (ja) | 咀嚼可能外層を有する配合剤 | |
JP6796132B2 (ja) | 液体剤形中の薬学的活性化合物放出性多層微小粒子 | |
US20190133977A1 (en) | Delayed release oral tamsulosin hydrochloride | |
JP6887043B2 (ja) | コルヒチンの徐放性製剤およびその使用方法 | |
AU2016202502A1 (en) | Oral Cephalotaxine Dosage Forms | |
AU2013270484A1 (en) | Oral Cephalotaxine Dosage Forms | |
JPH11510514A (ja) | 経口被覆活性薬物 | |
Pratap | Formulation and Evaluation of Duloxetine Hydrochloride Delayed Release Capsules | |
Hadi | Development and evaluation of mini-tablets-filed-capsule system for chronotherapeutic delivery of montelukast |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: Swiss Qiao Na Patentee after: TEVA PHARMACEUTICALS INTERNATIONAL GmbH Address before: La Perth, Switzerland Patentee before: Ivax International Ltd. Address after: New South Wales, Australia Patentee after: Chemical Gene Pharmaceutical Co.,Ltd. Address before: Vitoria Australia Patentee before: Chemical Gene Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20160825 Address after: La Perth, Switzerland Patentee after: Ivax International Ltd. Address before: New South Wales, Australia Patentee before: Chemical Gene Pharmaceutical Co.,Ltd. Effective date of registration: 20160825 Address after: Vitoria Australia Patentee after: Chemical Gene Pharmaceutical Co.,Ltd. Address before: American California Patentee before: CHEMGENEX PHARMACEUTICALS, Inc. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160427 Termination date: 20180414 |
|
CF01 | Termination of patent right due to non-payment of annual fee |